Vivani Medical Inc
NASDAQ:VANI

Watchlist Manager
Vivani Medical Inc Logo
Vivani Medical Inc
NASDAQ:VANI
Watchlist
Price: 1.34 USD 0.75% Market Closed
Market Cap: 74m USD
Have any thoughts about
Vivani Medical Inc?
Write Note

Vivani Medical Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Vivani Medical Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Vivani Medical Inc
NASDAQ:VANI
Interest Income Expense
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Interest Income Expense
-$364m
CAGR 3-Years
1%
CAGR 5-Years
10%
CAGR 10-Years
-15%
Boston Scientific Corp
NYSE:BSX
Interest Income Expense
-$564m
CAGR 3-Years
N/A
CAGR 5-Years
2%
CAGR 10-Years
-11%
Stryker Corp
NYSE:SYK
Interest Income Expense
$127m
CAGR 3-Years
23%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Abbott Laboratories
NYSE:ABT
Interest Income Expense
-$247m
CAGR 3-Years
21%
CAGR 5-Years
17%
CAGR 10-Years
-12%
Intuitive Surgical Inc
NASDAQ:ISRG
Interest Income Expense
$315.7m
CAGR 3-Years
54%
CAGR 5-Years
21%
CAGR 10-Years
39%
No Stocks Found

Vivani Medical Inc
Glance View

Market Cap
74m USD
Industry
Health Care

Vivani Medical Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Emeryville, California and currently employs 15 full-time employees. The company went IPO on 2014-11-19. Vivani Medical, Inc., formerly Second Sight Medical Products, Inc., is a developer of implantable visual prosthetics that creates an artificial form of useful vision for blind individuals. The firm is the combination of Nano Precision Medical, Inc. (NPM) and Second Sight Medical Products, Inc. NPM is a biopharmaceutical business that develops miniaturized, subdermal drug implants utilizing its NanoPortal technology to enable long-term, near constant-rate delivery of medicines to treat chronic diseases. Its divisions include Drug Implant & Visual Protheses division. The firm's Drug Implant division is developing a portfolio of miniature drug implants which utilize its NanoPortal drug implant technology. Its lead product, NPM-119, is a GLP-1 receptor agonist under development to treat patients with type two diabetes. The firm's Visual Protheses division is developing implantable visual prostheses devices that are intended to deliver useful artificial vision to blind individuals.

VANI Intrinsic Value
0.45 USD
Overvaluation 66%
Intrinsic Value
Price

See Also

Back to Top